An interventional study of Workshop in Attention Deficit Disorder With Hyperactivity (ADHD) and Substance Use Disorder (SUD), sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by University Hospital, Brest · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France — 20 open to participants now, 20 under way, 2 of them phase 3. Attention Deficit Disorder with Hyperactivity · France.
Among the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, this one is the 47th largest by planned enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2026, is one of 42 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 81st registered.
1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →20 of the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 5–12
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 8–16
Nantes University Hospital · Sites in France
Ages 18–99
University Hospital, Tours · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 14 · Phase 4 2
First in 2000; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 39 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 80 across the 60 interventional studies, 95 across the 22 observational. Of the 46 that completed or were terminated, 10 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 82 have an industry lead sponsor. The 10 most frequent:
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
University Hospital, Brest has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
5 of the studies in Attention Deficit Disorder with Hyperactivity with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05832489Phase 3University Hospital, Strasbourg, FranceEEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders | 2027-05 |
| NCT06232226Nantes University HospitalAttention Deficit Hyperactivity Disorder | 2026-12-31 |
| NCT07440992Assistance Publique - Hôpitaux de ParisIdentification of Early Biomarkers of Pre-school ADHD | 2027-03-01 |
| NCT07204873University Hospital, GrenobleEvaluation of the LUSHA Digital Application for Children With ADHD - Feasibility Study | 2027-07 |
| NCT06594536Assistance Publique - Hôpitaux de ParisStudy of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Workshops with a small group of patients.
Other: Workshop
Assess the 5 workshops, co-constructed by the scientific committee and thanks to feedback from the qualitative study
80% of patients participated in the workshops
The primary outcome measure is the acceptability of the program to participants in the pilot workshops, gathered through: * Semi-structured pre- and post-intervention interviews * A Likert scale * Workshop participation rate (at least 80%)
Time frame: From enrollment to the end of wordshop at 6 months
SF-12 quality of life
The secondary outcome measure will be measured by the SF-12 quality of life, before and after the 5 workshops. The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
Time frame: From enrollment to the end of wordshop at 6 months
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
Time frame: Data will be available after the publication of result and ending fifteen years following the last visit of the last patient.
Access criteria: Data access requests will be reviewed by the internal committee of BrestUH. Requestors will be required to sign and complete a data access agreement.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.
Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 16 months is below that.
Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →